Semaglutide | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
CDMO Prospector
- Demo Dashboard
Drugs in Dev.
News
Blog
Market Place
Login

Semaglutide
Health Canada Patents

PharmaCompass Sponsored Ads

Contact Supplier

CCSB Semaglutide

Contact Supplier

Semaglutide

Contact Supplier

Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

Contact Supplier

Semaglutide

Contact Supplier

Semaglutide

Contact Supplier

Semaglutide

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

156 API Suppliers, 53 USDMF, 13 KDMF, 73 NDC API, 53 Listed Suppliers, $ API Reference Price

156 API Suppliers
53 USDMF
13 KDMF
73 NDC API
53 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

330 Drugs in Development

330 Drugs in Development

INTERMEDIATES

17 Intermediate Suppliers

17 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

74 FDF Dossiers, 17 FDA Orange Book, 12 Europe, 11 Canada, 4 Australia, 2 South Africa, 28 Listed Dossiers

74 FDF Dossiers
17 FDA Orange Book
12 Europe
11 Canada
4 Australia
2 South Africa
28 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

SOLUTION;SUBCUTANEOUS - 2MG/3ML (0.68MG/ML), SOLUTION;SUBCUTANEOUS - 2MG/1.5ML (1.34MG/ML), SOLUTION;SUBCUTANEOUS - 4MG/3ML (1.34MG/ML), SOLUTION;SUBCUTANEOUS - 8MG/3ML (2.68MG/ML)

SOLUTION;SUBCUTANEOUS - 2MG/3ML (0.68MG/ML)
SOLUTION;SUBCUTANEOUS - 2MG/1.5ML (1.34MG/ML)
SOLUTION;SUBCUTANEOUS - 4MG/3ML (1.34MG/ML)
SOLUTION;SUBCUTANEOUS - 8MG/3ML (2.68MG/ML)

RELATED EXCIPIENT COMPANIES

1 Nanjing Well Pharmaceutical, 1 BASF, 1 Finar, 1 Valens Pharmachem

1 Nanjing Well Pharmaceutical
1 BASF
1 Finar
1 Valens Pharmachem

EXCIPIENTS BY APPLICATIONS

3 Topical, 2 Film Formers & Plasticizers, 2 Solubilizers, 1 Emulsifying Agents, 1 Thickeners and Stabilizers, 1 Parenteral

3 Topical
2 Film Formers & Plasticizers
2 Solubilizers
1 Emulsifying Agents
1 Thickeners and Stabilizers
1 Parenteral

DIGITAL CONTENT

9 Data Compilation #PharmaFlow, 13 Stock Recap #PipelineProspector, 573 News #PharmaBuzz

9 Data Compilation #PharmaFlow
13 Stock Recap #PipelineProspector
573 News #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 12 Regulatory FDF Prices, 16 Annual Reports

3 US Medicaid Prescriptions
12 Regulatory FDF Prices
16 Annual Reports

MARKET PLACE

63 APIs, 7 FDF Dossiers

63 APIs
7 FDF Dossiers

PATENTS & EXCLUSIVITIES

163 US Patents, 16 US Exclusivities, 5 Health Canada Patents

163 US Patents
16 US Exclusivities
5 Health Canada Patents

$ API Ref.Price (USD/KG) : 490,306 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

5 All

01 5Novo Nordisk Canada Inc.

filter Patent Reset all filters

5 All

01 52601784

filter Product Reset all filters

5 All

01 5SEMAGLUTIDE

filter Dosage Reset all filters

5 All

01 2SOLUTION

02 3TABLET

filter Exp Date Reset all filters

5 All

01 52026-03-20

Bachem Semaglutide

Product Main Page

01

Novo Nordisk Canada Inc.

SEMAGLUTIDE

Coatings Trends

Not Confirmed

Novo Nordisk Canada Inc.

Country

Coatings Trends

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-03-20

Date Granted : 2013-12-24

SEMAGLUTIDE

Brand Name : OZEMPIC

Patent Number : 2601784

Filing Date : 2006-03-20

Strength per Unit : 1.34 mg / mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : SUBCUTANEOUS

Patent Expiration Date : 2026-03-20

Date Granted : 2013-12-24

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

02

Novo Nordisk Canada Inc.

SEMAGLUTIDE

Coatings Trends

Not Confirmed

Novo Nordisk Canada Inc.

Country

Coatings Trends

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-03-20

Date Granted : 2013-12-24

SEMAGLUTIDE

Brand Name : OZEMPIC

Patent Number : 2601784

Filing Date : 2006-03-20

Strength per Unit : 1.34 mg / mL

Dosage Form : SOLUTION

Human Or VET : Human

Route of Administration : SUBCUTANEOUS

Patent Expiration Date : 2026-03-20

Date Granted : 2013-12-24

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

03

Novo Nordisk Canada Inc.

SEMAGLUTIDE

Coatings Trends

Not Confirmed

Novo Nordisk Canada Inc.

Country

Coatings Trends

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-03-20

Date Granted : 2013-12-24

SEMAGLUTIDE

Brand Name : RYBELSUS

Patent Number : 2601784

Filing Date : 2006-03-20

Strength per Unit : 3 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2026-03-20

Date Granted : 2013-12-24

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

04

Novo Nordisk Canada Inc.

SEMAGLUTIDE

Coatings Trends

Not Confirmed

Novo Nordisk Canada Inc.

Country

Coatings Trends

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-03-20

Date Granted : 2013-12-24

SEMAGLUTIDE

Brand Name : RYBELSUS

Patent Number : 2601784

Filing Date : 2006-03-20

Strength per Unit : 7 mg

Dosage Form : TABLET

Human Or VET :

Route of Administration : ORAL

Patent Expiration Date : 2026-03-20

Date Granted : 2013-12-24

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

05

Novo Nordisk Canada Inc.

SEMAGLUTIDE

Coatings Trends

Not Confirmed

Novo Nordisk Canada Inc.

Country

Coatings Trends

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2026-03-20

Date Granted : 2013-12-24

SEMAGLUTIDE

Brand Name : RYBELSUS

Patent Number : 2601784

Filing Date : 2006-03-20

Strength per Unit : 14 mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2026-03-20

Date Granted : 2013-12-24

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!